Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
05/2012
05/15/2012CA2398229C Improved dna vaccines for production-type animals
05/15/2012CA2288307C Novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same
05/10/2012WO2012061815A2 RABIES GLYCOPROTEIN VIRUS-LIKE PARTICLES (VLPs)
05/10/2012WO2012061811A2 Treatment method for lung remodeling diseases
05/10/2012WO2012061759A2 Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
05/10/2012WO2012061637A2 Hsv-1 epitopes and methods for using same
05/10/2012WO2012061599A2 Vaccines against toxoplasma gondii
05/10/2012WO2012061590A1 Cytotoxic agents comprising new ansamitocin derivatives
05/10/2012WO2012061558A2 Dual variable domain immunoglobulins and uses thereof
05/10/2012WO2012061548A1 Dock-and-lock (dnl) constructs for human immunodeficiency virus (hiv) therapy
05/10/2012WO2012061400A2 Method for reduction of free polysaccharide in polysaccharide-protein vaccines reactions using ion-exchange matrices
05/10/2012WO2012061374A2 Dual variable domain immunoglobulins and uses thereof
05/10/2012WO2012061289A2 Methods for treatment of brain injury utilizing biologics
05/10/2012WO2012061239A2 Novel vaccines against pandemic influenza virus a/h1n1
05/10/2012WO2012061203A1 Enhancement of pathogen-specific memory th17 cell responses
05/10/2012WO2012061120A1 Therapeutic composition for treatment of glioblastoma
05/10/2012WO2012061074A1 METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS
05/10/2012WO2012060025A1 Production of neutral antibody to human herpes virus 6 glycoprotein q1 and analysis thereof
05/10/2012WO2012059928A2 Antivenom
05/10/2012WO2012059858A1 Anti-her3 antibodies and compositions
05/10/2012WO2012059857A2 Pan-her antibody composition
05/10/2012WO2012059702A1 Process for producing an emulsifying composition based on hydrogenated lecithin
05/10/2012WO2012059696A1 Method for improving the production of influenza viruses and vaccine seeds
05/10/2012WO2012059598A2 Methods of treating rheumatoid arthritis using il-17 antagonists
05/10/2012WO2012059593A1 Vaccines for preventing meningococcal infections
05/10/2012WO2012059584A1 High-efficiency catalysts, preparation and use thereof
05/10/2012WO2012059562A1 C-met antibody combinations
05/10/2012WO2012059561A1 Anti c-met antibodies
05/10/2012WO2012059556A1 Novel antigen of enterococcal pathogens and use thereof as vaccine component for therapy and/or prophylaxis
05/10/2012WO2012059513A1 Mmp8 inactivating antigen binding proteins
05/10/2012WO2012059224A1 Immunotherapy against erbb-3 receptor
05/10/2012WO2012059112A1 Development of medical products based on a new discovered function of red blood cells
05/10/2012WO2012058957A2 Polysaccharide extracts of epimedium, fractions thereof and uses thereof in vaccine adjuvants
05/10/2012WO2012058935A1 Total polysaccharides of radix isatidis and their fractions, and uses thereof as vaccine adjuvants
05/10/2012WO2012058769A1 Method of treating mucosal inflammation
05/10/2012WO2012058768A1 Stable heterodimeric antibody design with mutations in the fc domain
05/10/2012WO2012058763A1 Synthetic lethality in cancer
05/10/2012WO2012036392A3 Human anti-epidermal growth factor receptor fab antibody and a pharmaceutical composition for treating tumours comprising the same
05/10/2012WO2012035330A3 Vaccines against leptospira
05/10/2012WO2012032169A9 Vaccine against n. meningitidis
05/10/2012WO2012027570A3 Dual variable domain immunoglobulins and uses thereof
05/10/2012WO2012027324A3 Treatment for neoplastic diseases
05/10/2012WO2012026309A9 Creation of anti-pad4 antibody pharmaceutical
05/10/2012WO2012018767A3 Antibodies directed against il-17
05/10/2012WO2012018380A3 Compositions and methods for inducing immune tolerance
05/10/2012WO2011160119A3 Anti-gd2 antibodies
05/10/2012WO2011109415A3 Reducing viscosity of pharmaceutical formulations
05/10/2012WO2011067673A3 Circulation of components during microfluidization and/or homogenization emulsions
05/10/2012WO2010069532A8 Antibodies against human angiopoietin 2
05/10/2012US20120117672 Isolation and growth of stem cells from hemangiomas
05/10/2012US20120117670 Humanized axl antibodies
05/10/2012US20120117669 Human antibodies derived from immunized xenomice
05/10/2012US20120115161 Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth
05/10/2012US20120114746 Immunostimulatory Compositions Comprising Liposome-Encapsulated Oligonucleotides and Epitopes
05/10/2012US20120114742 Polymer Conjugates with Decreased Antigenicity, Methods of Preparation and Uses Thereof
05/10/2012US20120114739 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
05/10/2012US20120114734 Nanostructure surface coated medical implants and methods of using the same
05/10/2012US20120114708 Integrin heterodimer and an alpha subunit thereof
05/10/2012US20120114704 Compounds, compositions and methods of treating cancer and fibrotic diseases
05/10/2012US20120114703 Botulinum Toxin Administration to Treat Various Conditions
05/10/2012US20120114702 Compositions and methods for treating asthma and other lung disorders
05/10/2012US20120114699 Allergoids Derived from Allergens
05/10/2012US20120114698 Salmonella marker vaccine
05/10/2012US20120114697 Treatment of holocrine gland dysfunction with clostridia neurotoxins
05/10/2012US20120114696 Small-molecule botulinum toxin inhibitors
05/10/2012US20120114695 Hsv-1 and hsv-2 vaccines and methods of use thereof
05/10/2012US20120114694 Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
05/10/2012US20120114693 Nucleic acid mucosal immunization
05/10/2012US20120114692 Immunogenic compositions containing phospholipid
05/10/2012US20120114691 Vaccine against african horse sickness virus
05/10/2012US20120114688 Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
05/10/2012US20120114687 Tuberculosis vaccines comprising antigens expressed during the latent infection phase
05/10/2012US20120114686 Compositions and methods related to protein a (spa) variants
05/10/2012US20120114685 Compositions comprising angiogenic factors and methods of use thereof
05/10/2012US20120114684 Compounds and methods for treatment and diagnosis of chlamydial infection
05/10/2012US20120114683 Nucleic Acid Encoding TGEV and PRRSV Sequences for Improved Expression of PRRSV Sequences
05/10/2012US20120114682 Peptides for binding fibrinogen and fibrin
05/10/2012US20120114681 Use of specific peptides in the preparation of a medicament for the treatment of monoclonal gammopathy of undetermined significance (mgus) or of smoldering multiple myeloma (smm)
05/10/2012US20120114680 Dendritic Cell Compositions and Methods
05/10/2012US20120114679 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
05/10/2012US20120114678 Treatment for nephritis
05/10/2012US20120114677 Modified nicotinic compounds and related methods
05/10/2012US20120114676 Methods of treating cancer with phenformin
05/10/2012US20120114674 Molecular Antigen Array
05/10/2012US20120114673 Compositions and methods for the diagnosis and treatment of tumor
05/10/2012US20120114672 Antibodies Specific to Cadherin-17
05/10/2012US20120114671 Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
05/10/2012US20120114670 Methods and compositions related to synergistic responses to oncogenic mutations
05/10/2012US20120114669 Compositions and method for the diagnosis, prevention and treatment of alzheimer's disease
05/10/2012US20120114668 Method for modulating angiogenesis using fibromodulin
05/10/2012US20120114667 TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
05/10/2012US20120114666 Neurological autoimmune disorders
05/10/2012US20120114665 Human antibodies to human rankl
05/10/2012US20120114664 Antibodies against h5n1 strains of influenza a virus
05/10/2012US20120114663 Methods to treat allergic conditions
05/10/2012US20120114662 Human monoclonal antibodies against bacillus anthracis protective antigen
05/10/2012US20120114661 Methods of identifying infectious disease and assays for identifying infectious disease
05/10/2012US20120114660 Antibodies Against LLG Polypeptides of the Triacylglycerol Lipase Family
05/10/2012US20120114659 Antibodies for Guanylyl Cyclase Receptors
05/10/2012US20120114658 Treatment of cancer
1 ... 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 ... 1823